NASDAQ:INNTInnovate Biopharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Innovate Biopharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.49 +0.01 (+2.08 %) (As of 04/9/2020 04:00 PM ET) Add Compare Share Today's Range$0.48Now: $0.49▼$0.5350-Day Range$0.39MA: $0.53▼$0.7552-Week Range$0.37Now: $0.49▼$2.40Volume166,183 shsAverage Volume543,268 shsMarket Capitalization$20.25 millionP/E RatioN/ADividend YieldN/ABeta-1.12 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Innovate Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company's lead product candidate is INN-202 that has completed Phase IIb clinical trial for the treatment of celiac disease. It also develops INN-108, which has completed Phase I clinical trial to treat mild-to-moderate ulcerative colitis; INN-217 for the treatment of non-alcoholic steatohepatitis and microbiome; and INN-289 to treat crohn's disease, as well as product for the treatment of alcoholic steatohepatitis (ASH). In addition, the company holds rights for INN-329, a formulation of secretin that is used to enhance visualization in magnetic resonance cholangiopancreatography procedures that is in Phase III clinical trial. The company has a research collaboration with Massachusetts General Hospital for the treatment of ASH. Innovate Biopharmaceuticals, Inc. is based in Raleigh, North Carolina.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Innovate Biopharmaceuticals. Previous Next 2.4 Community Rank Outperform VotesInnovate Biopharmaceuticals has received 203 “outperform” votes. (Add your “outperform” vote.)Underperform VotesInnovate Biopharmaceuticals has received 214 “underperform” votes. (Add your “underperform” vote.)Community SentimentInnovate Biopharmaceuticals has received 51.32% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Innovate Biopharmaceuticals and other stocks. Vote “Outperform” if you believe INNT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe INNT will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldInnovate Biopharmaceuticals does not currently pay a dividend.Dividend GrowthInnovate Biopharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Innovate Biopharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.90% of the stock of Innovate Biopharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 6.77% of the stock of Innovate Biopharmaceuticals is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Innovate Biopharmaceuticals are expected to grow by 17.24% in the coming year, from ($0.58) to ($0.68) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Innovate Biopharmaceuticals is -0.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Innovate Biopharmaceuticals is -0.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.61 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:INNT Previous Symbol CUSIPN/A CIK1551986 Webhttp://www.innovatebiopharma.com/ Phone919-275-1933Debt Debt-to-Equity RatioN/A Current Ratio0.35 Quick Ratio0.35Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.27) per share Price / Book-1.81Profitability EPS (Most Recent Fiscal Year)($0.98) Net Income$-27,050,000.00 Net MarginsN/A Return on EquityN/A Return on Assets-234.42%Miscellaneous Employees8 Outstanding Shares41,325,000Market Cap$20.25 million Next Earnings Date5/8/2020 (Estimated) OptionableOptionable Receive INNT News and Ratings via Email Sign-up to receive the latest news and ratings for INNT and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:INNT Rates by TradingView Innovate Biopharmaceuticals (NASDAQ:INNT) Frequently Asked Questions How has Innovate Biopharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Innovate Biopharmaceuticals' stock was trading at $0.4715 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, INNT stock has increased by 3.9% and is now trading at $0.49. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Innovate Biopharmaceuticals? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innovate Biopharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Innovate Biopharmaceuticals. When is Innovate Biopharmaceuticals' next earnings date? Innovate Biopharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, May 8th 2020. View our earnings forecast for Innovate Biopharmaceuticals. How were Innovate Biopharmaceuticals' earnings last quarter? Innovate Biopharmaceuticals Inc (NASDAQ:INNT) posted its quarterly earnings data on Monday, March, 18th. The company reported ($0.11) earnings per share for the quarter, hitting the Zacks' consensus estimate of ($0.11). View Innovate Biopharmaceuticals' earnings history. Has Innovate Biopharmaceuticals been receiving favorable news coverage? News articles about INNT stock have been trending very negative recently, according to InfoTrie. The research firm identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Innovate Biopharmaceuticals earned a news impact score of -3.3 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutInnovate Biopharmaceuticals. Are investors shorting Innovate Biopharmaceuticals? Innovate Biopharmaceuticals saw a increase in short interest in the month of March. As of March 13th, there was short interest totaling 2,243,800 shares, an increase of 7.9% from the February 27th total of 2,080,000 shares. Based on an average daily trading volume, of 215,300 shares, the short-interest ratio is presently 10.4 days. Currently, 7.9% of the shares of the stock are sold short. View Innovate Biopharmaceuticals' Current Options Chain. Who are some of Innovate Biopharmaceuticals' key competitors? Some companies that are related to Innovate Biopharmaceuticals include TFF Pharmaceuticals (TFFP), SCYNEXIS (SCYX), TapImmune (MRKR), Adamas Pharmaceuticals (ADMS), ESSA Pharma (EPIX), Cyclerion Therapeutics (CYCN), Clearside Biomedical (CLSD), SUMMIT THERAPEU/S (SMMT), Genprex (GNPX), Xeris Pharmaceuticals (XERS), Monopar Therapeutics (MNPR), Galmed Pharmaceuticals (GLMD), Elite Pharmaceuticals (ELTP), Catabasis Pharmaceuticals (CATB) and Arbutus Biopharma (ABUS). What other stocks do shareholders of Innovate Biopharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Innovate Biopharmaceuticals investors own include NIO (NIO), Corbus Pharmaceuticals (CRBP), AcelRx Pharmaceuticals (ACRX), Axsome Therapeutics (AXSM), Iterum Therapeutics (ITRM), Momo (MOMO), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), Progenics Pharmaceuticals (PGNX) and Sorrento Therapeutics (SRNE). Who are Innovate Biopharmaceuticals' key executives? Innovate Biopharmaceuticals' management team includes the following people: Mr. Sandeep Laumas M.D., CEO & Exec. Chairman (Age 50)Mr. Jay P. Madan M.S., Founder, Pres, Chief Bus. Officer, Interim Principal Fin & Accounting Officer and Director (Age 53)Dr. Christopher P. Prior, Consultant (Age 66)Jerry Gardner M.D., Head of Clinical StrategyDr. Patrick H. Griffin, Chief Medical Officer (Age 64) What is Innovate Biopharmaceuticals' stock symbol? Innovate Biopharmaceuticals trades on the NASDAQ under the ticker symbol "INNT." How do I buy shares of Innovate Biopharmaceuticals? Shares of INNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Innovate Biopharmaceuticals' stock price today? One share of INNT stock can currently be purchased for approximately $0.49. How big of a company is Innovate Biopharmaceuticals? Innovate Biopharmaceuticals has a market capitalization of $20.25 million. The company earns $-27,050,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis. Innovate Biopharmaceuticals employs 8 workers across the globe. View additional information about Innovate Biopharmaceuticals. What is Innovate Biopharmaceuticals' official website? The official website for Innovate Biopharmaceuticals is http://www.innovatebiopharma.com/. How can I contact Innovate Biopharmaceuticals? Innovate Biopharmaceuticals' mailing address is 8480 HONEYCUTT ROAD SUITE 120, RALEIGH NC, 27615. The company can be reached via phone at 919-275-1933 or via email at [email protected] This page was last updated on 4/9/2020 by MarketBeat.com StaffFeatured Article: Pattern Day Trader - What is the PDT Rule?
